Dalen Meeter - 21 Feb 2025 Form 4 Insider Report for Singular Genomics Systems, Inc.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
25 Feb 2025, 20:11:40 UTC
Prior SEC filing
11 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dalen Meeter

Key filing fact

Dalen Meeter filed Form 4 for Singular Genomics Systems, Inc. on 25 Feb 2025.

Key facts

  • This page summarizes Dalen Meeter's Form 4 filing for Singular Genomics Systems, Inc..
  • 7 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 25 Feb 2025, 20:11.

Change

  • Previous filing in this sequence was filed on 11 Feb 2025.
  • Current net transaction value: -$157,480.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OMIC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-9,502
Change %
-100%
Price
Shares after
0
Date
21 Feb 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OMIC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-833
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
833
Exercise price
$660.00
Footnotes
F2, F3
OMIC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-1,666
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,666
Exercise price
$268.50
Footnotes
F2, F3
OMIC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-6,249
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,249
Exercise price
$225.00
Footnotes
F2, F3
OMIC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-6,666
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,666
Exercise price
$38.40
Footnotes
F2, F3
OMIC transaction Derivative

Restricted Stock Unit

Disposed to Issuer

Transaction value
$120,000
Shares
-6,000
Change %
-100%
Price
$20.00
Shares after
0
Date
21 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,000
Exercise price
Footnotes
F4, F5
OMIC transaction Derivative

Restricted Stock Unit

Disposed to Issuer

Transaction value
$37,480
Shares
-1,874
Change %
-100%
Price
$20.00
Shares after
0
Date
21 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,874
Exercise price
Footnotes
F4, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Dalen Meeter is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

Footnote F2

As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Footnote F3

Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

Footnote F4

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F5

The RSU was subject to a service-based vesting condition over a four-year period in 16 equal quarterly installments measured from February 9, 2024. As of the Effective Time, the vesting of the RSU was accelerated in full. Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in the preceding sentence, each vested RSU was canceled and automatically converted into the right to receive, without interest and less any applicable tax withholdings, $20.00 in cash.

Footnote F6

The RSU was subject to a service-based vesting condition over a four-year period in 16 equal quarterly installments measured from March 15, 2023. As of the Effective Time, the vesting of the RSU was accelerated in full. Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in the preceding sentence, each vested RSU was canceled and automatically converted into the right to receive, without interest and less any applicable tax withholdings, $20.00 in cash.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .